Wells Fargo’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-262
Closed 7070
2019
Q3
$0 Hold
262
﹤0.01% 7030
2019
Q2
$0 Hold
262
﹤0.01% 6870
2019
Q1
$0 Sell
262
-203
-44% -$199 ﹤0.01% 6792
2018
Q4
$0 Hold
465
﹤0.01% 6881
2018
Q3
$1K Buy
465
+1
+0.2% +$1 ﹤0.01% 6358
2018
Q2
$0 Buy
464
+9
+2% +$3 ﹤0.01% 6853
2018
Q1
$0 Buy
455
+1
+0.2% +$1 ﹤0.01% 6797
2017
Q4
$0 Buy
454
+450
+11,250% +$517 ﹤0.01% 6780
2017
Q3
$0 Buy
4
+1
+33% +$1 ﹤0.01% 6707
2017
Q2
$0 Sell
3
-50
-94% -$57 ﹤0.01% 6734
2017
Q1
$0 Hold
53
﹤0.01% 6765
2016
Q4
$0 Buy
53
+1
+2% +$1 ﹤0.01% 6705
2016
Q3
$0 Sell
52
-24
-32% -$29 ﹤0.01% 6614
2016
Q2
$0 Sell
76
-4
-5% -$5 ﹤0.01% 6692
2016
Q1
$0 Buy
80
+76
+1,900% +$102 ﹤0.01% 6766
2015
Q4
$0 Hold
4
﹤0.01% 6744
2015
Q3
$0 Hold
4
﹤0.01% 6824
2015
Q2
$0 Hold
4
﹤0.01% 6778
2015
Q1
$0 Hold
4
﹤0.01% 6685
2014
Q4
$0 Sell
4
-10
-71% -$34 ﹤0.01% 6750
2014
Q3
$0 Sell
14
-187
-93% -$545 ﹤0.01% 6645
2014
Q2
$0 Buy
201
+187
+1,336% +$517 ﹤0.01% 6586
2014
Q1
$0 Hold
14
﹤0.01% 6407
2013
Q4
$0 Hold
14
﹤0.01% 6298
2013
Q3
$0 Sell
14
-2,596
-99% -$20K ﹤0.01% 6159
2013
Q2
$19K Buy
+2,610
New +$18.9K ﹤0.01% 4893

Wells Fargo's CELGZ Position: Q4 2019 in Review

Wells Fargo sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2019, closing a stake of 262 shares.

Wells Fargo first reported a position in CELGZ in Q2 2013 and held it in 26 quarters. The position peaked at $19K in Q2 2013. 0 funds tracked by Wall St. Rank hold CELGZ as of Q4 2019.

  • Wells Fargo reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
  • Wells Fargo sold 262 Celgene Corporation Contingent Value Rights shares in Q4 2019.
  • Wells Fargo first reported a position in Celgene Corporation Contingent Value Rights in Q2 2013 and held it in 26 quarters.
  • Wells Fargo's Celgene Corporation Contingent Value Rights position peaked at $19K in Q2 2013.
  • 0 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2019.

Based on Wells Fargo's 13F filing for Q4 2019, filed 14 Feb 2020.